Simon Says “Don’t Do This” (1.27.2022)
Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.
Hydroxychloroquine Dose and Risk for Incident Retinopathy
A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy.
Worse Birth Outcomes in RA and SLE
A population-based retrospective cohort study patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and their infants demonstrated significant adverse pregnancy outcome, particularly the infants of women with SLE.
2022 Rheumatology Year in Review (1-6-2023)
Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.
2022 Rheumatology Year in Review
2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.
Best of 2022: Approach to ILD in Myositis Syndromes
Editor's note: this article originally appeared July 28, 2022, and is being shared again as a Best of 2022. Enjoy!
ACR22 Takeaways: Pre-RA, Lupus, PsA and AS
ACR22 Convergence left us bountiful with information from all over the world. Here are a few of my personal highlights.
ACR 2022 Appraisal, Praise & Critique (11.18.2022)
It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle.
I loved the city, but not the convention center (not easy to navigate).
ACR Best Abstracts - Day 2
Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty selections for #ACRbest abstracts today:
ACR Best Abstracts - Day 1
The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).
Don’t be ‘ticked’: TYK2 is not a JAK!
Recently the FDA approved deucravacitinib (DEUC), a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in systemic lupus erythematosus.
Industry Abstract Previews of ACR 2022
The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022. These are their best studies for you to review and evaluate as part of your to-do list.
Social
Causes of Carpal Tunnel Syndr: obesity, repetitive wrist movements, pregnancy, RA, PsA. but also Sjögren's syndrome, Behcet's disease and systemic sclerosis (weaker) https://t.co/ssrs8UJEpX
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Medical literature review of suggests low vitamin D status is common in Rheumatic pts. & low vit D levels linked to loss of muscle strength, MSK pain, sarcopenia & falls (esp in IIM, PMR, SLE, RA, SSc) (BUT DOES REPLACING VITAMIN D FIX THESE PROBLEMS???) https://t.co/30IiKj7l4d https://t.co/ydU6FQMTi5
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
Cross-sectional study of 154 adult DLE pts in the Philadelphia area assessed DLE Dz severity (by CLASI) & geoghraphic distribution to ID area deprivation (ADI). ADI > 5 (geospatial disadvantaged) was assoc w/ signif (4X) higher risk of mod-Severe Damage https://t.co/dgeGwzNTKm https://t.co/B3hmUE1G9U
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
UK study of pneumococcal vaccination in UK, shows IMID pts had suboptimal vax against pneumococcus. In 32 277 pts (RA 14151, IBD 13631, SpA 3804, SLE 691) saw 57% vaccinated; lower if <45 yrs (32%), IBD (42%). Vax not associated w/ IMID flare https://t.co/y5JHYaEpA9 https://t.co/zUXfDoqyal
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
Factors Affecting Hydroxychloroquine Adherence
A study from the University of British Columbia has evaluated the trajectories of HCQ use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence.
https://t.co/kDUxVCfRGt https://t.co/1v79Vqdqo8
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/7hJeTf3O6y https://t.co/V43YHjhEhn
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Recommendation for management of fatigue in people with rheumatic disease.
Considering fatigue as a surrogate for inflammation and changing medication accordingly is part of it.
I will also add yearly blood work including:
1- VitD
2-HBA1c and LDl
3-TsH. https://t.co/3QvPqMxZSN
Links:
Nouf Al hemmadi @NoufAhmedAlham2 ( View Tweet )
1 year 6 months ago
#EULAR2024 Please find our Day 1 & Day 2 Recap of selective abstracts/research presented at the conference 😃@RheumNow @DrMiniDey
https://t.co/AHl18gS7gF https://t.co/LEoa9rBNly
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 6 months ago
#SARD #ILD
Who to screen for #rheumatic #diseases
For
ILD
#ACR guidelines
Screening May also depend on ILD prevalence
Not sure if frequency of screening and how to screen
@jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6
Links:
Janet Pope @Janetbirdope ( View Tweet )
1 year 6 months ago
